Interview: António Portela, CEO, Bial Portugal
António Portela, CEO of Portugal’s flagship pharmaceutical company Bial, talks about the recent approval of Aptiom by the FDA, the first Portuguese drug to ever to be approved in the…
Founded in 1924, BIAL is today the biggest Portuguese pharmaceutical group with a team of about 900 collaborators, and with a strong commitment to R&D, internationalization and quality.
BIAL is also an international pharmaceutical group with business activities in more than 50 countries. Based in Portugal, Bial owns facilities in Spain—where a production unit and a R&D centre dedicated to allergic immunotherapy are situated—Italy, Mozambique, Panama, and other countries.
Strongly committed to therapeutic innovation, investing more than 20 percent of its turnover in R&D every year, BIAL Group has launched the first drug of Portuguese patent, an anti-epileptic. Available since 2009 in several European markets, under the brand Zebinix, this antiepileptic, eslicarbazepine acetate, has recently been approved by the regulator of the pharmaceutical market in the US, Food and Drug Administration (FDA), for commercialization in the United States under the brand Aptiom.
BIAL has also a second pharmaceutical for its own research, for the treatment of the Parkinson disease, which is already in an advanced development process (phase III of clinical development).
The company expects to introduce more new medicines and vaccines to the market in the next years, specifically in the central nervous system, the cardiovascular system and allergen immunotherapy, which will be an added impetus to its international expansion.
Since 2005 the Bial Group is a member of the “European Federation of Pharmaceutical Industries and Associations” (EFPIA), which has recognized Bial as a research and development pharmaceutical company capable of bringing new medicines to the world to improve human health and the quality of life of the populations.
Bial Group has also been distinguished by its support to several medical and scientific activities, namely through BIAL Foundation, having as outstanding events the BIAL Award and Scientific Research Grants, well recognized worldwide.
Bial Contact Info:
À Av. da Siderurgia Nacional
4745-457 S. Mamede do Coronado – Portugal
Phone: +351 22986 6100 | Fax: +351 22986 6190
www.bial.com | info@bial.com
António Portela, CEO of Portugal’s flagship pharmaceutical company Bial, talks about the recent approval of Aptiom by the FDA, the first Portuguese drug to ever to be approved in the…
Filipe Novais leads the Portuguese affiliate for Astellas during an exciting time for the company globally. With a new global CEO, Astellas is aiming to be at the forefront of…
Jorge Sequeira, general manager for Cerner Portugal, sheds light on Portuguese prowess in healthcare technology. Jorge covers themes ranging from revolutionizing electronic medical records (EMR), uptake of new technologies in…
Mario Madeira, general manager of Teva Portugal, highlights the milestones of the affiliate in Portugal, referencing the economic crisis and where Teva is now positioned in the country. In addition,…
RJ Lasek took on his first country lead position in Portugal in 2016 and has successfully reshaped the affiliate to match global operations, forecasting 40 percent growth for 2018. In…
Similar to many Western economies, Portugal is attempting to embrace digitalization in healthcare, but unlike Europe’s Big Five which struggle due to huge populations and decentralized systems, thanks to Portugal’s…
Portugal’s Minister of Health, Adalberto Campos Fernandes, details his three-tiered plan for national health in Portugal. He explains that empowering citizens, transforming the sector digitally and ensuring that the proximity…
Experienced country manager, João Madeira, introduces Mylan’s new vision to be a global healthcare company serving patients across the world with their hybrid generic, OTC and innovative pharmaceutical business model…
Quilaban, a Portuguese healthcare solutions company located in the Sintra business district of West Lisbon, has been led by Sérgio Luciano for five years. Luciano provides an insightful vision into…
Alnylam, pioneers in the RNA interference field, seek to bring their revolutionary medicine across Europe, and in particular Portugal before 2020. In this interview the new General Manager for Spain…
Henrique Manuel Gil Martins, chairman of SPMS (Shared services of the Ministry of Health) provides an insight into the uptake of technology in Portugal’s Ministry of Health and National Health…
Hailing from the Dominican Republic, Silvia Guichardo brings a fresh perspective as well as both US and Iberian experience to GSK Portugal. Six months into her role as general manager,…
Filipe Paias, general manager for Baxter International Portugal, illustrates the organizational change Baxter has undergone in the past three years, in both process, strategy, and reputation. In Portugal, Baxter is…
See our Cookie Privacy Policy Here
